Prime Therapeutics recently entered into an outcomes-based contract with Boehringer Ingelheim as part of its CareCentered Contracting program. The collaboration is for Jardiance (empagliflozin), an oral type 2 diabetes medicine indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease.

This CareCentered Contracting agreement will focus on the total cost of care for members taking Jardiance and comparing that to the total cost of care for patients taking other diabetic medications. In this manner, Prime can truly evaluate the combined cost of pharmacy and medical on select therapies and its impact on overall health costs. 

“Because diabetes affects nearly 10 percent of the U.S. population, Prime actively works to find solutions that can improve our members’ health outcomes and control the overall costs of diabetes,” said Jonathan Gavras, M.D., chief medical officer at Prime. “Establishing a CareCentered Contracting agreement for Jardiance allows us to collect and analyze important data beyond pharmacy claims. These insights help drive the greatest value from the treatment.”

“We’re pleased to enter into this outcomes-based contract with Prime, which represents an important step towards improving outcomes by lowering the total cost of care of people with diabetes,” said Christine Marsh, vice president, Market Access, Boehringer Ingelheim. “Diabetes and cardiovascular disease put a significant financial burden on the healthcare system, and we are confident Jardiance may improve outcomes by reducing the overall healthcare costs of people with type 2 diabetes and cardiovascular disease.” 

Jardiance adds to Prime’s portfolio of CareCentered Contracting agreements in the diabetes category and the comprehensive treatment of diabetes is an area of strategic focus for Prime.